i don't know what to expect, but it should be good, this is a serious advancement that will be integrated into standard blood panels world wide, huge upside, i know everyone is anxious but bgms's day will come
Android why are you so down on this stock - I am not starting a fight just interested in your take - my 38000 dollars seems small to some but it is all I have to invest
Thank you Steve, do you expect news soon - my goal is to hold on to half my shares until the call and keep the rest until we have a sale or hit 10
please do your own DD - gradual upswing and news - we see a 6 dollar stock easy - sold MCP for a nice profit
and not many buyers here....
its done moving up with that picutre....any sellers coming in should move this lower....
We may hope that some news will be released this week due to March 4 listing requirement (Nasdaq) and the estimated date for revenues that is also set to mid March..
All this waiting has to end at some point!
I am hoping and leaning towards the "BO" option.....it honestly would not make business sense for them to not mention BGMD in their PR partnering relationship on Galectin-3 Assay platform without reason.
Sentiment: Strong Buy
There must be a good reason for them not mentioning BGMD. Perhaps since they have not yet issued official PR on FDA clearance and Launch time frame thus they don't want to give too much info until then. Who knows? But we will find out soon or at earnings CC.
Sentiment: Strong Buy
Why wouldn't Abbott mention who they were working for/with on the FDA clearance. Abbott mentions several times thru out the call of who they work with, but leave out BG. Medicine. I mean bgmd paid them right? The g3 test is owned by BGMD?. Actually a shame how small the FDA mention was in content. Comes off as a Oh by the way statement...
In the fourth quarter we received US FDA clearance for the first fully automated galectin 3 test for use with our ARCHITECT platform. This test assists doctors in assessing the prognoses of people diagnosed with chronic heart failure.
Additionally, a study on our high-sensitive component test previously launched on ARCHITECT generated new data that was recently published in the British Medical Journal. The study found that Abbott 's tests can precisely measure very low levels of troponin, which may help doctors accurately diagnose twice as many heart attacks in women compared to standard troponin tests.